Ranirestat: A selective aldose reductase inhibitor for diabetic sensorimotor polyneuropathy

Journal of Pharmacy Technology

Volumn 24, Issue 6, 2008, Pages 340-344

  Vo, Ty ^a   Marcus, Kristine B ^b  

^a PACIFIC UNIVERSITY   (United States)

^b Pacific University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALRESTATIN; EPALRESTAT; FIDARESTAT; MINALRESTAT; PONALRESTAT; RANIRESTAT; SORBINIL; SX 3030; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SELECTIVITY; EMBASE; ENZYME INHIBITION; FEVER; HUMAN; HYPERURICOSURIA; ISOMER; KIDNEY FUNCTION; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LYMPHADENOPATHY; MEDLINE; OUTCOMES RESEARCH; PANCYTOPENIA; PHOTOSENSITIVITY; POLYNEUROPATHY; RASH; REVIEW; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; STEREOISOMERISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 58149250322     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250802400605     Document Type: Review

References (18)

1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22.
2. Boru UT, Alp R, Sargin H, et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocr J 2004;51:563-7.
3. Ismail K, Winkley K, Stahl D, Chalder T, Edmunds M. A cohort study of people with diabetes and their first foot ulcer: the role of depression on mortality. Diabetes Care 2007;30:1473-9.
4. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007;67:569-85.
5. Kles KA, Bril V. Diagnostic tools for diabetic sensorimotor polyneuropathy. Curr Diabetes Rev 2006;2:353-61.
6. Boucek P. Advanced diabetic neuropathy: a point of no return? Rev Diabet Stud 2006;3:143-50.
7. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007 Oct 17;(4):CD004572. DOI 10.1002/14651858.CD004572.pub2
8. Benbow SJ, Wallymahmed ME, MacFalane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-7.
9. Ziegler D. Treatment of diabetic polyneuropathy: update 2006. Ann N Y Acad Sci 2006;1084:250-66.
10. Varkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 2008;10:99-108.
11. Giannoukakis N. Drug evaluation: ranirestat - an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr Opin Invest Drugs 2006;7:916-23.
12. Kurono M, Fujiwara I, Yoshida K. Stereospecific interaction of a novel spirosuccinamide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 2001;40:8216-26.
13. Safety and efficacy of AS-3201 in the treatment of diabetic sensorimotor polyneuropathy, NCT00101426. Bethesda MD: US National Institutes of Health. www.clinicaltrials.gov (accessed 2008 Jan 15).
14. Bril V, Buchanan RA, AS-3201 study group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004;27:2369-75.
15. Bril V, Buchanan RA, Ranirestat study group. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29:68-72.
16. Bril V, Perkins BA, Ranirestat study group. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25:2048-52.
17. Yokoyama Y. Drug research overview. R & D Meeting March 28, 2007. Dainippon Sumitomo Pharma Co., Ltd. www.ds-pharma.co.jp/english/ir/presentation/ img/rd.2007.03.pdf (accessed 2008 Jan 15).
18. Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs 2008;17:575-81.